Randomized investigation of heart failure therapy in patients with advanced cancer at risk of cardiac wasting: Rationale and design of the EMPATICC trial

Heart Failure

Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure

Circulation

Berg DD, Patel SM, Haller PM, Cange AL, Palazzolo MG, Bellavia A, Kuder JF, Desai AS, Inzucchi SE, McMurray JJV, O'Meara E, Verma S, Bělohlávek J, Drożdż J, Merkely B, Ogunniyi MO, Drasnar T, Izzo JL, Sarman B, McGinty JE, Ramanathan K, Mulkay AJ, Przybylski A, Ruff CT, O'Donoghue ML, Murphy SA, Sabatine MS, Wiviott SD, DAPA ACT HF-TIMI 68 Trial Committees and Investigators

doi: 10.1161/CIRCULATIONAHA.125.076575

Heart, Artery and Coronary Diseases

Encouraging the prescribing of SGLT2i and GLP-1RA medications to reduce cardiovascular and renal risk in patients with type 2 diabetes: rationale and design of a randomized controlled trial

Am Heart J

Haff N, Horn DM, Bhatkhande G, Sung M, Colling C, Wood W, Robertson T, Gaposchkin D, Simmons L, Yang J, Yeh J, Crum KL, Hanken KE, Lauffenburger JC, Choudhry NK

doi: 10.1016/j.ahj.2025.02.007

Heart Failure

Implementation of guideline-recommended therapies in heart failure with reduced ejection fraction according to heart failure duration: An analysis of 55 581 patients from the Swedish Heart Failure (SwedeHF) Registry

Eur J Heart Fail

Shahim A, Linde C, Savarese G, Dahlström U, Lund LH, Hage C

doi: 10.1002/ejhf.3565

Heart Failure

Effects of dapagliflozin on blood volume status and vascular outcomes in clinically stabilized heart failure patients after an acute decompensated heart failure event (DAPA-VOLVO study): Protocol of a double-blind randomized controlled clinical trial

PLoS One

Bitos K, Laptseva N, Haider T, Rossi VA, Nägele MP, Barthelmes J, Ruschitzka F, Sudano I, Flammer AJ

doi: 10.1371/journal.pone.0325668

Further Publications

Clinical and echocardiographic phenotype of cardiac wasting in patients with advanced cancer

Eur J Heart Fail

Anker MS, Khan MS, Nikolski A, Porthun J, Arshad MS, Hadzibegovic S, Lena A, Kretzler L, Hella JL, Witkowski M, Rieger K, Ahn J, Modest DP, Keller U, Bullinger L, Totzeck M, Mahabadi AA, Rassaf T, Buchmann N, Attanasio P, Zeller T, Karakas M, Tocchetti CG, Wilkenshoff U, Cleland JGF, von Haehling S, Butler J, Landmesser U

doi: 10.1002/ejhf.3744

Heart Failure

Characteristics and outcomes of patients with heart failure and history of malignancy: Data from Swedish Heart Failure Registry and the National Cancer Register

Eur J Heart Fail

Ameri P, Costa P, Benson L, Stolfo D, Sayour NV, Ljungman C, Butler J, Anker SD, Girerd N, Keramida K, Filippatos G, Lund LH, Lindberg F, Savarese G

doi: 10.1002/ejhf.3775

Heart Failure

Burst steroid therapy and quality of life in patients with acute heart failure: Insights from the CORTAHF trial

ESC Heart Fail

Pagnesi M, Cotter G, Davison BA, Freund Y, Voors AA, Edwards C, Novosadova M, Takagi K, Hayrapetyan H, Mshetsyan A, Drambyan M, Cohen-Solal A, Ter Maaten JM, Biegus J, Ponikowski P, Filippatos G, Chioncel O, Sadoune M, Simon T, Mann DL, Mebazaa A, Metra M

doi: 10.1002/ehf2.15235

Heart Failure

Rationale, Design, and Baseline Characteristics of the Virtual Care to Improve Heart Failure Outcomes (VITAL-HF) Trial

Am Heart J

Khan MS, Sauer AJ, Green CL, McDermott J, Khan MS, Chaudhry SP, Haghighat AR, Bennett MK, Martyn T, Shah H, Govil A, Stanis T, Albert NM, DeVore AD

doi: 10.1016/j.ahj.2025.06.001

Heart Failure

Clinical utility and safety of finerenone in patients with heart failure: Rationale and design of FINE registry

ESC Heart Fail

Alonso Salinas GL, Martínez León A, Aguiar Cano D, Esteban-Fernández A, Viéitez Flórez JM, Del Prado Díaz S, Górriz-Magaña J, de Lara Delgado G, González-Manzanares R, Caravaca-Pérez P, Pastor-Pérez FJ, Valdivieso-Moré S, Quiles J, Ponz I, Escolar V, Boada Lincango EO, Báez-Ferrer N, Gallego G, Almenar L, Gutiérrez de la Varga L, Codina P, Recio Mayoral A, Fort A, Pinilla Lozano MJ, González-Calle D, Gómez-Otero I, Salazar Mosteiro C, Cobo M, Piqueras-Flores J, Bonanad C, Huerta A, Ferré Vallverdú M, Díez-Villanueva P

doi: 10.1002/ehf2.15260

Related content

Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure

Encouraging the prescribing of SGLT2i and GLP-1RA medications to reduce cardiovascular and renal risk in patients with type 2 diabetes: rationale and design of a randomized controlled trial

Implementation of guideline-recommended therapies in heart failure with reduced ejection fraction according to heart failure duration: An analysis of 55 581 patients from the Swedish Heart Failure (SwedeHF) Registry

Effects of dapagliflozin on blood volume status and vascular outcomes in clinically stabilized heart failure patients after an acute decompensated heart failure event (DAPA-VOLVO study): Protocol of a double-blind randomized controlled clinical trial

Clinical and echocardiographic phenotype of cardiac wasting in patients with advanced cancer

Characteristics and outcomes of patients with heart failure and history of malignancy: Data from Swedish Heart Failure Registry and the National Cancer Register

Burst steroid therapy and quality of life in patients with acute heart failure: Insights from the CORTAHF trial

Rationale, Design, and Baseline Characteristics of the Virtual Care to Improve Heart Failure Outcomes (VITAL-HF) Trial

Clinical utility and safety of finerenone in patients with heart failure: Rationale and design of FINE registry